AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · Real-Time Price · USD
3.790
-0.050 (-1.30%)
Nov 21, 2025, 4:00 PM EST - Market closed
AVITA Medical Stock Forecast
Stock Price Forecast
The 4 analysts that cover AVITA Medical stock have a consensus rating of "Buy" and an average price target of $11.75, which forecasts a 210.03% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $21.
Price Target: $11.75 (+210.03%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AVITA Medical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Sell → Hold Upgrades n/a | Strong Sell → Hold | Upgrades | n/a | n/a | Nov 20, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +269.39% | Nov 7, 2025 |
| Lake Street | Lake Street | Strong Buy → Hold Downgrades $8 → $4 | Strong Buy → Hold | Downgrades | $8 → $4 | +5.54% | Oct 17, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +269.39% | Oct 17, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +269.39% | Sep 15, 2025 |
Financial Forecast
Revenue This Year
77.08M
from 64.25M
Increased by 19.96%
Revenue Next Year
102.84M
from 77.08M
Increased by 33.43%
EPS This Year
-1.27
from -2.39
EPS Next Year
-0.64
from -1.27
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 82.4M | 124.4M | |||
| Avg | 77.1M | 102.8M | |||
| Low | 69.7M | 79.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.3% | 61.4% | |||
| Avg | 20.0% | 33.4% | |||
| Low | 8.4% | 3.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.27 | -0.13 | |||
| Avg | -1.27 | -0.64 | |||
| Low | -1.73 | -1.35 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.